Fortress Biotech Inc
FBIOP
Company Profile
Business description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Contact
1111 Kane Concourse
Suite 301
Bay Harbor IslandFL33154
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
101
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,347.20 | 11.56 | -0.14% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,200.13 | 390.07 | -0.79% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 26,848.47 | 239.99 | 0.90% |
| NASDAQ | 23,655.29 | 78.61 | -0.33% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,952.81 | 24.46 | -0.35% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,138.76 | 26.53 | -0.64% |